Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal


          Year.

Following the extraordinary general meeting of shareholders (the "Extraordinary General Meeting") of RVL Pharmaceuticals plc, formerly Osmotica Pharmaceuticals plc (the "Company"), held on January 14, 2022, the results of which are summarized in Item 5.07 below, the Company has applied for, and received, a Certificate of Registration on Change of Name (the "Name Change Certificate") from the Irish Companies Registration Office. The Name Change Certificate changed the name of the Company from "Osmotica Pharmaceuticals plc" to "RVL Pharmaceuticals plc", effective as of January 17, 2022. Consequent amendments to the Company's Constitution, reflecting the name change, have been made and filed with the Irish Companies Registration Office (the "Constitution Amendment").

The foregoing summary description of the Constitution Amendment is qualified in its entirety by reference to the full text thereof, which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

Item 5.07 Submission of Matters to a Vote of Security Holders.

At the Extraordinary General Meeting, the Company's shareholders approved the proposal to change the Company's name from Osmotica Pharmaceuticals plc to RVL Pharmaceuticals plc, based on the following votes:





   For        Against    Abstain
47,809,014   1,635,376   60,268


Item 8.01 Other Events

In connection with the Company's name change, the Company's ordinary shares will continue trading on the Nasdaq Global Select Market under the new ticker symbol, RVLP, effective January 19, 2022. The Company's CUSIP number will not change.





Item 9.01 Exhibits




(d) Exhibits.



Exhibit
No.                                     Description
  3.1        Memorandum and Articles of Association of RVL Pharmaceuticals plc
104        Cover Page Interactive Data File (formatted as Inline XBRL)

© Edgar Online, source Glimpses